Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Nitschmann

Showing results (11-20 of 222) with videos related to

Pageof 23
Sort By:
Der Internist|February 11, 2021
[Mortality of lung cancer]Felix Herth, S Nitschmann
Der Internist|May 20, 2021
[Evinacumab in patients with treatment-refractory hypercholesterolemia]Eberhard Windler, S Nitschmann
Der Internist|May 5, 2017
[Bezlotoxumab for the secondary prevention of Clostridium difficile infection : MODIFY I and MODIFY II studies]C Lübbert, S Nitschmann
Der Internist|September 5, 2018
[Potential new treatment strategies for B‑cell lymphomas]M Heuser, S Nitschmann
Der Internist|October 29, 2011
[Prevention in chronic obstructive pulmonary disease. POET-COPD (prevention of exacerbations with tiotropium in COPD)]A Gillissen, S Nitschmann
Der Internist|October 18, 2011
[Therapy of hepatitis delta. The Hep-Net International Delta Hepatitis Intervention Trial]J Nattermann, S Nitschmann
Der Internist|March 14, 2012
[Non-steroidal anti-inflammatory drugs for patients with hypertension and coronary artery disease]W Mühlberg, S Nitschmann
Der Internist|April 1, 2004
[Therapy of chronic heart failure--carvedilol vs. metoprolol. COMET Study]G Ertl, S Nitschmann
Der Internist|February 27, 2010
[Lung cancer: genetic screening before starting therapy]J Wolf, S Nitschmann
Der Internist|December 5, 2015
[New therapy option for type 2 diabetes mellitus: EMPA-REG study]E Windler, S Nitschmann
Pageof 23

Showing results (11-20 of 222) with videos related to

Sort By:
Pageof 23
Der Internist|February 11, 2021
[Mortality of lung cancer]Felix Herth, S Nitschmann
Der Internist|May 20, 2021
[Evinacumab in patients with treatment-refractory hypercholesterolemia]Eberhard Windler, S Nitschmann
Der Internist|May 5, 2017
[Bezlotoxumab for the secondary prevention of Clostridium difficile infection : MODIFY I and MODIFY II studies]C Lübbert, S Nitschmann
Der Internist|September 5, 2018
[Potential new treatment strategies for B‑cell lymphomas]M Heuser, S Nitschmann
Der Internist|October 29, 2011
[Prevention in chronic obstructive pulmonary disease. POET-COPD (prevention of exacerbations with tiotropium in COPD)]A Gillissen, S Nitschmann
Der Internist|October 18, 2011
[Therapy of hepatitis delta. The Hep-Net International Delta Hepatitis Intervention Trial]J Nattermann, S Nitschmann
Der Internist|March 14, 2012
[Non-steroidal anti-inflammatory drugs for patients with hypertension and coronary artery disease]W Mühlberg, S Nitschmann
Der Internist|April 1, 2004
[Therapy of chronic heart failure--carvedilol vs. metoprolol. COMET Study]G Ertl, S Nitschmann
Der Internist|February 27, 2010
[Lung cancer: genetic screening before starting therapy]J Wolf, S Nitschmann
Der Internist|December 5, 2015
[New therapy option for type 2 diabetes mellitus: EMPA-REG study]E Windler, S Nitschmann
Pageof 23